Is Carpisetin/Toncordin a targeted drug?

Capivasertib belongs to the category of targeted drugs. The so-called targeted drugs refer to a type of anti-cancer drugs that can specifically act on abnormal molecules or signaling pathways in cancer cells to accurately inhibit tumor growth. Unlike traditional chemotherapy, targeted drugs are usually based on molecular mechanisms and aim to improve treatment selectivity and reduce damage to normal cells.

Carpisetin targets the AKT pathway AKT is a key node of the PI3K/AKT/mTOR signaling pathway, which plays a central role in regulating cell proliferation, metabolism and survival. In many cancers, due to mutations or inactivation of genes such as PIK3CA, AKT1, or PTEN, the AKT pathway is abnormally activated, resulting in cancer cells acquiring sustained growth and resistance to apoptosis.

As a selective pan-AKT inhibitor, Capisete tablets can inhibit the activity of multiple subtypes of the AKT family, thereby effectively blocking tumor cell-dependent signaling and achieving the purpose of inhibiting tumor development. Clinical study results further verify its status as a targeted drug. In the phase III CAPItello-291 study, capicipositin combined with fulvestrant showed improved efficacy in patients with HR-positive/HER2-negative advanced breast cancer, especially in patients with PIK3CA/AKT1/PTEN gene alterations. This fully demonstrates that carpisetin works through molecular targets, rather than indiscriminately killing cells like chemotherapy.

It is worth emphasizing that, as a targeted drug, capisete tablets are not without side effects. Since theAKT pathway is also involved in metabolism and regulation in normal tissues, its application may still cause adverse reactions such as rash, diarrhea, or increased blood sugar. However, most of these side effects can be managed through dose adjustment or supportive treatment, and the clinical acceptability is good.

In summary, carpisetin is a clear targeted drug that achieves precise anti-tumor effects by inhibiting theAKT signaling pathway. Its emergence not only provides new treatment options for drug-resistant breast cancer patients, but also represents a new direction in the development of tumor molecular targeted therapy.

Reference materials:https://www.drugs.com/mtm/capivasertib.html